lactic acid injection (STA363) / Stayble Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lactic acid injection (STA363) / Stayble Therap
STA-02, NCT04673461 / 2019-004943-54: Study Investigating STA363 Compared to Placebo in Patients With Chronic Discogenic Low Back Pain

Active, not recruiting
2
110
Europe, RoW
STA363 containing 90 mg (60 mg/mL) lactic acid, STA363 containing 180 mg (120 mg/mL) lactic acid, Placebo
Stayble Therapeutics, Stayble Therapeutics AB
Discogenic Pain
09/23
10/23
2021-006503-15: A prospective, randomised, double-blinded, placebo-controlled study investigating the safety and tolerability in patients with radiculopathy caused by lumbar disc herniation.

Not yet recruiting
1/2
24
Europe
STA363, STA363, Solution for injection
Stayble Therapeutics, Stayble Therapeutics
Radiculopathy due to lumbar intervertebral disc herniation, Radiculopathy due to lumbar intervertebral disc herniation, Diseases [C] - Nervous System Diseases [C10]
 
 
NCT06022263 / 2021-006503-15: STA363 in the Treatment of Lumbar Disc Herniation

Recruiting
1
24
Europe
Lactic Acid, STA363, Placebo
Stayble Therapeutics, Cromsource, Antaros Medical, VIEDOC
Lumbar Disc Herniation
05/24
08/24

Download Options